Cytovale

Executive Summary

Cytovale is a private medical diagnostics company headquartered in San Francisco, founded in 2013. The company has developed and commercialized the Cytovale System, an FDA-cleared platform that runs the IntelliSep test, a rapid diagnostic for early sepsis detection in adult emergency department patients. The test analyzes the biomechanical properties of white blood cells to assess immune activation and stratify sepsis risk within approximately 8 minutes, offering a significant speed advantage over traditional lab-based methods. This innovation addresses a critical unmet need in emergency medicine, where early sepsis intervention dramatically improves patient outcomes and reduces healthcare costs. The sepsis diagnostics market is large and growing, driven by rising sepsis incidence and awareness. Cytovale competes with other rapid sepsis tests and biomarker panels, but its unique biomechanical approach and 510(k) clearance provide a solid regulatory foundation. As a private company, Cytovale likely relies on venture funding and partnerships to scale commercialization. Near-term focus is expected to include expanding hospital adoption, seeking reimbursement from payers like CMS, and potentially developing next-generation versions or pediatric indications. The company's ability to secure reimbursement and strategic partnerships will be critical to its growth trajectory.

Upcoming Catalysts (preview)

• Q2 2027CMS Reimbursement Decision for IntelliSep Test65% success
• Q4 2026Expansion of FDA Clearance to Pediatric Indication50% success
• Q3 2026Strategic Commercial Partnership with Major Hospital System70% success